These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 30428847)

  • 41. Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study).
    Lee HW; Park JY; Kim BK; Kim MY; Lee JI; Kim YS; Yoon KT; Han KH; Ahn SH
    Clin Mol Hepatol; 2016 Dec; 22(4):443-449. PubMed ID: 27880997
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Park JG; Park SY
    Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Kim K; Kitrinos KM; Subramanian GM; McHutchison JG; Yee LJ; Elkhashab M; Berg T; Sporea I; Yurdaydin C; Husa P; Jablkowski MS; Gane E
    J Hepatol; 2017 Jan; 66(1):11-18. PubMed ID: 27545497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The risk of adefovir monotherapy in human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients.
    Gelinck LB; Claas EC; Kroon FP
    J Hepatol; 2005 Aug; 43(2):360-1; author reply 361. PubMed ID: 15970350
    [No Abstract]   [Full Text] [Related]  

  • 45. Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication.
    Schinazi RF; Bassit L; Clayton MM; Sun B; Kohler JJ; Obikhod A; Arzumanyan A; Feitelson MA
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6186-91. PubMed ID: 22985879
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
    Lada O; Gervais A; Branger M; Peytavin G; Roquebert B; Collin G; Fraqueiro G; Moucari R; Leclerc L; Martinot-Peignoux M; Matheron S; Marcellin P
    Antivir Ther; 2012; 17(1):61-70. PubMed ID: 22267470
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
    van Bömmel F; Zöllner B; Sarrazin C; Spengler U; Hüppe D; Möller B; Feucht HH; Wiedenmann B; Berg T
    Hepatology; 2006 Aug; 44(2):318-25. PubMed ID: 16871563
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B.
    Lee YB; Jung EU; Kim BH; Lee JH; Cho H; Ahn H; Choi WM; Cho YY; Lee M; Yoo JJ; Cho Y; Lee DH; Cho EJ; Yu SJ; Park SJ; Kim YJ; Park JW; Lee YJ; Kim CM; Yoon JH; Kim CY; Lee HS
    Antimicrob Agents Chemother; 2015 Feb; 59(2):972-8. PubMed ID: 25421484
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.
    Archampong TN; Lartey M; Sagoe KW; Obo-Akwa A; Kenu E; Gillani FS; Yang H; Boamah I; Flanigan T; Kwara A
    BMC Infect Dis; 2016 Jan; 16():14. PubMed ID: 26759172
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus.
    Greenup AJ; Tan PK; Nguyen V; Glass A; Davison S; Chatterjee U; Holdaway S; Samarasinghe D; Jackson K; Locarnini SA; Levy MT
    J Hepatol; 2014 Sep; 61(3):502-7. PubMed ID: 24801414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
    Berg T; Marcellin P; Zoulim F; Moller B; Trinh H; Chan S; Suarez E; Lavocat F; Snow-Lampart A; Frederick D; Sorbel J; Borroto-Esoda K; Oldach D; Rousseau F
    Gastroenterology; 2010 Oct; 139(4):1207-17. PubMed ID: 20600025
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Long-term therapy for chronic hepatitis B in HIV co-infected patients].
    Pais R; Benhamou Y
    Gastroenterol Clin Biol; 2010 Sep; 34 Suppl 2():S136-41. PubMed ID: 21095517
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir treatment in lamivudine-resistant HBV-infected patients with or without HIV infection.
    Cortez KJ; Proschan MA; Barrett L; Brust DG; Weatherley B; Formentini E; Davey RT; Masur H; Polis MA; Neumann And AU; Kottilil S
    HIV Clin Trials; 2013; 14(4):149-59. PubMed ID: 23924587
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
    Jain MK; Comanor L; White C; Kipnis P; Elkin C; Leung K; Ocampo A; Attar N; Keiser P; Lee WM
    J Viral Hepat; 2007 Mar; 14(3):176-82. PubMed ID: 17305883
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China.
    Gu L; Han Y; Li Y; Zhu T; Song X; Huang Y; Yang F; Guan S; Xie J; Gohda J; Hosoya N; Kawana-Tachikawa A; Liu W; Gao GF; Iwamoto A; Li T; Ishida T
    PLoS One; 2015; 10(8):e0134539. PubMed ID: 26288093
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
    Zhang MY; Zhu GQ; Shi KQ; Zheng JN; Cheng Z; Zou ZL; Huang HH; Chen FY; Zheng MH
    Oncotarget; 2016 May; 7(21):30642-58. PubMed ID: 27121321
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
    Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
    J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China.
    Wu YS; Zhang WW; Ling XM; Yang L; Huang SB; Wang XC; Wu H; Cai WP; Wang M; Wang H; Liu YF; He HL; Wei FL; Wu ZY; Zhang FJ
    Chin Med J (Engl); 2016 Feb; 129(3):304-8. PubMed ID: 26831232
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy.
    Gaglio PJ; Sterling R; Daniels E; Tedaldi E;
    Clin Infect Dis; 2007 Sep; 45(5):618-23. PubMed ID: 17682998
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.
    Childs K; Joshi D; Byrne R; Bruce M; Carey I; Agarwal K; Taylor C
    AIDS; 2013 Jun; 27(9):1443-8. PubMed ID: 23435302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.